Skip to search formSkip to main contentSkip to account menu

sacubitril / valsartan

Known as: SACUBITRIL/VALSARTAN, sacubitril-valsartan, valsartan and sacubitril 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

LCZ 696
sacubitrilvalsartan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice
Abstract: Little is known about the dosing and tolerability of sacubitril/valsartan (LCZ696; Entresto, Quebec, Canada) in a… 
2019
2019
Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation
Our aim was to describe the clinical profile of patients presenting sustained ventricular arrhythmias after sacubitril/valsartan… 
2019
2019
PRIOR EXPOSURE TO A CONVENTIONAL RENIN-ANGIOTENSIN SYSTEM ANTAGONIST AND ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITION IN ACUTE DECOMPENSATED HEART FAILURE: A PRESPECIFIED SUBGROUP ANALYSIS OF THE…
2019
2019
Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
BACKGROUND Clinical efficacy of sacubitril/ valsartan - administered for the recommended indication of patients with reduced(<40… 
2017
2017
Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).
Sacubitril/valsartan was compared to enalapril in the PARADIGM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor… 
2017
2017
Valsartan : The Newest Addition to the Toolbox for Guideline Directed Medical Therapy of Heart Failure
Sacubitril/valsartan combines a neprilysin inhibitor with an angiotensin receptor blocker. As an inhibitor of neprilysin, an… 
Review
2017
Review
2017
Pharmacologic Therapy for Heart Failure With Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and Practice.
2017
2017
Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
.
OBJECTIVES To assess the protein binding and pharmacokinetics of sacubitril/valsartan analytes (sacubitril, sacubitrilat, and… 
2017
2017
Profound Vasoplegia During Sacubitril/Valsartan Treatment After Heart Transplantation.
2017
2017
Sacubitril/Valsartan in an Elderly Patient with Heart Failure: A Case Report
Sacubitril/valsartan has recently been approved for the treatment of heart failure with reduced ejection fraction. Given its… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)